Hematologic Malignancies

John M. Burke MD Elias Jabbour MD Rami S. Komrokji MD and Shaji Kumar MD review and share their expert perspectives on key hematologic malignancy findings presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Share

Program Content

Activities

  • BRIGHT: 5-Yr Results
    BRIGHT: 5-Yr Follow-up of First-line BR vs R-CHOP/R-CVP in Pts With iNHL or MCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2017

    Expires: June 04, 2018

  • Daratumumab + KRd in NDMM
    Addition of Daratumumab to Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2017

    Expires: June 05, 2018

  • GENUINE: Ublituximab in R/R CLL
    GENUINE: Investigation of Ublituximab, a Novel CD20 Inhibitor, in Combination With Ibrutinib in Pts With Previously Treated High-Risk CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2017

    Expires: June 05, 2018

  • MAGNIFY: R/R FL Subanalysis
    MAGNIFY Subanalysis: Lenalidomide + Rituximab Induction Followed by Maintenance in Pts With Early Relapsed or Double-Refractory FL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2017

    Expires: June 06, 2018

  • NDMM Induction: KCd vs KRd
    FORTE: Induction With Carfilzomib, Dexamethasone, and Cyclophosphamide or Lenalidomide in Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2017

    Expires: June 06, 2018

  • Elotuzumab + RVD in ND MM
    Quadruple Therapy With Elotuzumab + RVD in Newly Diagnosed MM: Phase IIa Study
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2017

    Expires: June 06, 2018

  • PomdeSAR: Isatuximab in R/R MM
    PomdeSAR: Early Investigation of the Anti-CD38 Monoclonal Antibody Isatuximab in Combination With Pomalidomide/Dexamethasone in R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2017

    Expires: June 07, 2018

  • OPTIMAL>60: RT by PET Status in DLBCL
    OPTIMAL>60: Radiotherapy by PET Status After R-CHOP or R-CHLIP in Elderly Pts With DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2017

    Expires: June 07, 2018

  • Simplify 1: Momelotinib in MF
    Simplify 1: Momelotinib vs Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2017

    Expires: June 08, 2018

  • SIMPLIFY-2: Momelotinib vs BAT in MF
    SIMPLIFY-2: Momelotinib vs Best Available Therapy in Ruxolitinib-Experienced Pts With Myelofibrosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2017

    Expires: June 08, 2018

  • Enasidenib in IDH2-Mutant R/R AML
    Clinical Activity and Safety of IDH2 Inhibitor Enasidenib (AG-221) in IDH2-Mutant Relapsed/Refractory AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2017

    Expires: June 11, 2018

  • 19-28z CAR T-Cells in R/R B-ALL
    Phase I Trial of CD19-Targeted 19-28z CAR T-Cell Therapy in Adult Pts With R/R B-Cell ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2017

    Expires: June 11, 2018

  • CHRYSALIS: Molecular Responses With Gilteritinib
    CHRYSALIS Exploratory Analysis: Molecular Responses With FLT3/AXL Inhibitor Gilteritinib in Relapsed/Refractory FLT3-ITD AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2017

    Expires: June 13, 2018

  • MM: Denosumab vs ZA
    Phase III Trial: Bone and Renal Effects With Denosumab vs Zoledronic Acid in Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2017

    Expires: June 13, 2018

Provided by

ProCE Banner

Supporters

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology